β-blockers for congestive heart failure. What is the current consensus?

Drugs and Aging

Volumn 16, Issue 1, 2000, Pages 1-7

  Tsuyuki, Ross T ^a   McAlister, Finlay A ^a   Teo, Koon K ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LABETALOL; NEUROHORMONE;

ADRENERGIC SYSTEM; AGED; ARTICLE; ASSISTED CIRCULATION; BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; EXERCISE TOLERANCE; FATIGUE; HEART EJECTION FRACTION; HEART FUNCTION; HOSPITALIZATION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0033972014     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200016010-00001     Document Type: Article

References (54)

1. 1. McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham Study. N Engl J Med 1971; 285: 1441-6
2. 2. Yusuf S, Thom T, Abbot RD. Changes in hypertension and in congestive heart failure mortality. Hypertension 1989; 13 Suppl. I: I-74 I-79
3. 3. Kannel WB, Belanger AJ. Epidemiology in heart failure. Am Heart J 1991; 121: 951-7
4. 4. Schocken DD, Arricta MI, Leaverton PE. Prevalence in mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301-6
5. 5. Ho KKL, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-15
6. 6. Packer M, Cohn JN. Consensus recommendations for the management of chronic heart failure: on behalf of the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Am J Cardiol 1999; 83 Suppl. 2A: 1A-38
7. 7. Johnstone DE, Abdulla A, Arnold JMO, et al. Diagnosis and management of heart failure. Can J Cardiol 1994; 10: 613-31
8. 8. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-6
9. 9. Yusuf S, Teo K. Inotropic agents increase mortality in patients with congestive heart failure. Circulation 1990; 82 Suppl. III: 111-673
10. 10. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-75
11. 11. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-54
12. 12. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure: Evaluation of Losartan in the Elderly Study (ELITE). Lancet 1997; 349: 747-52
13. 13. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-23
14. 14. Eichhorn EJ, Bristow MR. Medial therapy can improve the biological properties of the chronically failing heart. Circulation 1996; 94: 2285-96
15. 15. Bristow M, Port JD. Beta adrenergic blockade in chronic heart failure. Scand Cardiovase J Suppl 1998; 47: 45-55
16. 16. Ikram H, Fitzpatrick D. Double-blind trial of chronic oral beta blockade in congestive cardiomyopathy. Lancet 1981; II (8245): 490-2
17. 17. Anderson JL, Lutz JR, Gilbert EM, et al. A randomimized trial of low-dose beta-blockade therapy for idiopathic dilated cardiomyopathy. Am J Cardiol 1985; 55: 471-5
18. 18. Engelmeier RS, O'Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985; 72: 536-46
19. 19. Cucchini F, Compostella L, Papalia D, et al. Trattamento cronico della cardiomiopatia dilatativa con betabloccanti. G Ital Cardiol 1988; 18: 835-42
20. 20. Gilbert EM, Anderson JL, Deitchman D, et al. Long-term betablocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 1990; 88: 223-9
21. 21. Leung W-H, Lau C-P, Wong C-K, et al. Improvement in exercise performance and hemodynamics by labetalol in patients with idiopathic dilated cardiomyopathy. Am Heart J 1990; 119: 884-90
22. 22. Pollock SG, Lystash J, Tedesco C, et al. Usefulness of bucindolol in congestive heart failure. Am J Cardiol 1990; 66: 603-7
23. 23. Woodley SL, Gilbert EM, Anderson JL, et al. Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991; 84: 2426-41
24. 24. Boutelant S, Lechat P, Komajda M, et al. Evaluation non invasive des effets cardiovasculaires du nébivolol chez l'insuffisant cardiaque [in French]. Arch Mal Coeur Vaiss 1992; 85: 863-70
25. 25. Paolisso G, Gambardella A, Marrazzo G, et al. Metabolic and cardiovascular benefits deriving from beta-adrenergic blockade in chronic congestive heart failure. Am Heart J 1992; 123: 103-10
26. 26. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993; 21: 1094-100
27. 27. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: a randomized double-blind, placebo-controlled study. J Am Coll Cardiol 1994; 24: 1310-20
28. 28. Bristow MR, O'Connell JB, Gilbert EM, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy: the bucindolol investigators. Circulation 1994; 89: 1632-42
29. 29. Fisher ML, Gottlieb SS, Plotnick GD, et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 1994; 23: 943-50
30. 30. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342: 1441-6
31. 31. CIBIS Investigators. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-73
32. 32. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13
33. 33. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349: 375-80
34. 34. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: the U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55
35. 35. Tsuyuki RT, Yusuf S, Rouleau JL, et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997; 13: 1166-74
36. 36. Zarembski DG, Nolan Jr PE, Slack MK, et al. Meta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic dilated cardiomyopathy. Am J Cardiol 1996; 77: 1247-50
37. 37. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997; 30: 27-34
38. 38. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta-blocker therapy on mortality in patients with heart failure. Eur Heart J 1997; 18: 560-5
39. 39. Lechat P, Packer M, Chalon S, et al. Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98: 1184-91
40. 40. Avezum A, Tsuyuki R, Pogue J, et al. Beta-blocker therapy for congestive heart failure: a systematic overview and critical appraisal of the published trials. Can J Cardiol 1998; 14: 1045-53
41. 41. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomized controlled trials. Lancet 1998; 351: 47-52
42. 42. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335-71
43. 43. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997; 79: 794-8
44. 44. Jansen RWMM, Gurwitz JH. Controversies surrounding the use of beta-blockers in older patients with cardiovascular disease. Drugs Aging 1994; 4: 175-83
45. 45. Gurwitz JH, Col NF, Avorn J. The exclusion of the elderly and women from clinical trials in acute myocardial infarction. JAMA 1992; 268: 1417-22
46. 46. McAlister FA, Taylor L, Teo KK, et al. The treatment and prevention of coronary heart disease in Canada: do older patients receive efficacious therapies? J Am Geriatr Soc 1999; 47: 811-18
47. 47. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-97
48. 48. Soumerai SB, McLaughlin TJ, Spiegelman D, et al. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction. JAMA 1997; 277: 115-21
49. 49. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction. JAMA 1998; 280: 623-9
50. 50. Bright RA, Everitt DE. Beta-blockers and depression: evidence against an association. JAMA 1992; 267: 1783-7
51. 51. Dimsdale JE, Newton RP, Joist T. Neuropsychological side effects of beta-blockers. Arch Intern Med 1989; 149; 514-25
52. 52. Dahlof C, Dimenas E, Kendall M, et al. Quality of life in cardiovascular diseases: emphasis on beta-blocker treatment. Circulation 1991; 84 Suppl. VI: 108-18
53. 53. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med 1991; 151: 1769-76
54. 54. Gurwitz JH, Avorn J. The ambiguous relation between aging and adverse drug reactions. Ann Intern Med 1991; 114: 956-66